Active Pharmaceutical Ingredient Market Size, Growth, Share & Trends Analysis
Report Code
PH 1262
Published in
Oct, 2025, By MarketsandMarkets™
Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape - Global forecast to 2030
USD 198.39 BN
MARKET SIZE, 2030
CAGR 6.6%
(2025-2030)
533
REPORT PAGES
692
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The active pharmaceutical ingredients market is projected to reach USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a CAGR of 6.6% from 2025 to 2030. The growth of the active pharmaceutical ingredients market is driven by the surge in demand for complex APIs, such as high-potency API, peptides, oligonucleotides, and increasing government incentives and supply chain reshoring.
KEY TAKEAWAYS
- The North America API market accounted for a 43.0% revenue share in 2024.
- By type, the innovative APIs market segment dominated the market with 61.0% share in 2024.
- By potency, the highly potent APIs segment is projected to grow at the fastest rate of 7.5% from 2025 to 2030.
- Based on the type of synthesis, biotech APIs segment is expected to grow at the highest CAGR over the forecast period.
- By type of drug, the prescription drugs segment accounts for the largest market share compared to over-the-counter (OTC) drugs.
- Based on the therapeutic applications, the communicable diseases segment is expected to grow fastest during the forecast period.
- Based on the end user segmentation, the pharmaceutical and biotechnology industry segment accounts for the major share in the market.
- Pfizer Inc., Divi’s Laboratories Limited, Cipla, Asymchem, Evonik Industries AG are key companies identified as some of the star players in the API market (global), given their strong market share and product footprint.
- Companies such as, Corden Pharma, MSN Laboratories, Laurus Labs, and Solara Active Pharma Sciences have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The active pharmaceutical ingredients market is witnessing steady growth, driven by the rising demand for innovative APIs to enhance the therapeutic efficacy of formulations. New deals and developments, including strategic partnerships between manufacturers and API suppliers, investments in facilities and manufacturing capacity expansion, and adoption of continuous manufacturing and quality process for API manufacturing, are reshaping the industry landscape.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on consumers' business emerges from customer trends or disruptions. Pharmaceutical and biotech companies have seen key changing trends and disruptions in the last few years, and are expected to accelerate in the forecast period. Shift towards chronic diseases, increasing adoption of personalized medicine and biologics, rise of GLP-1 drugs, and interest in anti-obesity therapies are some of the short and long-term shifts that are expected to drive changes in the demand from pharmaceutical and biologics customers of API suppliers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Surge in Demand for Complex APIs
-
Government Incentives & Supply Chain Reshoring
RESTRAINTS
Impact
Level
Level
-
Tightening Regulatory Requirements for Nitrosamine and Impurity Controls
-
High Production Costs in Western Facilities
OPPORTUNITIES
Impact
Level
Level
-
Critical Medicines Premium Pricing via Dual-sourcing and Local Manufacturing
-
China-Plus-One Strategy Boosting India, US, and EU Manufacturing Bases
CHALLENGES
Impact
Level
Level
-
Capital-intensive Investments for High- containment and Advanced Facilities
-
Quality Failures and Site Shutdowns
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Surge in Demand for Complex APIs
Significant surge in demand for complex APIs, including GLP-1, HPAPIs, peptides, oligonucleotides, and ADC payloads, is driving market growth. These high-value, structurally intricate molecules are pivotal in treating chronic, metabolic, and oncology-related conditions, fueling R&D investments and contract manufacturing activities. The new class of peptide-based drugs led by Semaglutide, Tirzepatide, and similar molecules like Liraglutide and Dulaglutide has not only transformed clinical outcomes but also put impetus on securing the API supply chain. Owing to the rising prevalence of diabetes, obesity is expected to increase the demand for targeted and personalized therapies.
Restraint: Tightening Regulatory Requirements for Nitrosamine and Impurity Controls
Since 2019, regulators, including the FDA and EMA, have steadily tightened impurity standards following high-profile nitrosamine contamination cases. The 2024 FDA final guidance has raised the bar further, requiring extensive risk assessment, advanced analytical controls, and reformulation in some cases. While these measures improve drug safety and quality, they significantly increase compliance costs, extend product timelines, and create operational challenges for manufacturers, especially those managing older generic APIs.
Opportunity: Critical Medicines Premium Pricing via Dual-sourcing and Local Manufacturing
Ongoing shortages of antibiotics and essential APIs have pushed governments, especially in Europe and North America, to incentivize local production and diversify sourcing. Initiatives like the EU Critical Medicines Act and India’s PLI scheme aim to reduce dependence on Asia and secure supply resilience. This shift creates opportunities for API manufacturers offering dual-sourcing or regional manufacturing, enabling them to command premium pricing, lock in long-term offtake agreements, and build more resilient customer relationships.
Challenge: Capital-Intensive Investments for High-Containment and Advanced Facilities
Producing HPAPIs, peptides, and oligonucleotides requires advanced high-containment facilities equipped with isolators, specialized reactors, and robust quality systems. Building such plants typically requires USD 100–300 million in investment, along with 3–5 years of construction and regulatory validation before commercial output. This presents a significant challenge for API suppliers: balancing the need for cutting-edge infrastructure to meet customer demand against the risk of under-utilization and margin pressure. Securing anchor clients or long-term contracts is often critical to justify these capital-intensive projects.
Active Pharmaceutical Ingredient Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Manufactures HPAPIs, oncology APIs, CNS drugs, and intermediates with global CDMO capabilities | Strong expertise in high-containment, reliable partner for complex oncology & specialty therapies, serving multiple pharma innovators |
 |
Global leader in generic APIs, including antivirals (HIV), CNS, and cardiovascular, alongside custom synthesis for innovators | Cost-efficient large-scale API production, benefits from India’s PLI scheme and China-plus-one strategy, and strong regulatory track record |
 |
Supplies corticosteroids, antibiotics, hormones, and niche small molecules; provides APIs both to Sanofi (captive) and global pharma clients (merchant) | Anchored by Sanofi long-term contracts, critical role in EU reshoring efforts, supports dual-sourcing for essential medicines |
 |
Operates one of the world’s largest API divisions, supplying across oncology, CNS, respiratory, and cardiovascular therapeutic areas | Diversified portfolio ensures global supply resilience, supports Teva’s generics while also supplying external clients, balancing captive + merchant roles |
 |
Specializes in peptides, lipids, and HPAPIs, including GLP-1 analogues and ADC payloads | Positioned in the fastest-growing therapy areas (metabolic & oncology); offers high-purity scalable synthesis; critical supplier in the obesity/diabetes pipeline |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The active pharmaceutical ingredients (API) market ecosystem consists of raw material suppliers (e.g., Thermo Fisher, Avantor), API manufacturers (e.g., Divi’s Laboratories, Pfizer, Siegfried), and end users such as pharmaceutical and biotechnology companies (e.g., Amgen, Gilead). Raw materials like chemical intermediates, solvents, and key starting materials (KSMs) are processed into APIs through advanced chemical synthesis, fermentation, or biologics manufacturing. End users drive demand by developing innovative therapies in oncology, metabolic disorders, and rare diseases, while manufacturers deliver high-quality, compliant APIs at commercial and clinical scales. Collaboration across the value chain, from secure sourcing of raw materials to reliable supply of APIs for finished formulations, is essential to ensure innovation, supply chain resilience, and sustainable market growth.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Active Pharmaceutical Ingredients Market, By Type
As of 2024, innovative APIs held the largest share of the API market and are expected to maintain their leadership through 2030 due to the expanding pipeline of novel drugs in oncology, immunology, and rare diseases, coupled with sustained R&D investments from global pharma and biotech companies. The rise of biologics, peptides, oligonucleotides, and highly potent APIs (HPAPIs) further strengthens this segment, as these complex molecules require advanced manufacturing capabilities and offer higher margins than generic APIs. Additionally, continued regulatory approvals, patent protections, and growing adoption of personalized and precision medicines will drive long-term demand for innovative APIs worldwide.
Active Pharmaceutical Ingredients Market, By Potency
In 2024, traditional APIs dominated the active pharmaceutical ingredients (API) market, driven by their widespread use across chronic disease treatments, large-scale generic drug production, and broad therapeutic coverage in areas such as cardiovascular, central nervous system, and anti-infective therapies. Their relatively lower manufacturing complexity, established production infrastructure, and cost-effectiveness further supported their dominance, making them the backbone of branded generics and essential medicines worldwide.
Active Pharmaceutical Ingredients Market, By Synthesis
The synthetic segment is expected to dominate the active pharmaceutical ingredients (API) market, owing to its established large-scale manufacturing infrastructure, lower production costs, and broad application across generic and branded drugs. Synthetic APIs are widely used in treating chronic conditions such as cardiovascular diseases, diabetes, and infectious diseases, which account for a significant share of global pharmaceutical demand. Additionally, strong availability of raw materials, standardized production processes, and the ability to achieve economies of scale further reinforce the dominance of synthetic APIs over the forecast period.
Active Pharmaceutical Ingredients Market, By Type of Drug
In 2024, prescription drugs dominated the active pharmaceutical ingredients (API) market, driven by the rising prevalence of chronic and complex diseases, increasing demand for specialty medicines in oncology, immunology, and rare disorders, and the continued development of innovative therapies and biologics. Strong regulatory approvals, higher R&D investments by pharmaceutical and biotechnology companies, and the need for APIs in patented drugs and high-value generics further reinforced the dominance of the prescription drug segment over over-the-counter (OTC) drugs.
Active Pharmaceutical Ingredients Market, By Therapeutic Applications
In 2024, communicable diseases dominated the active pharmaceutical ingredients (API) market, owing to the high global burden of infectious diseases, ongoing demand for antibiotics, antivirals, and antifungals, and the continued need for treatment of HIV, hepatitis, tuberculosis, and emerging viral outbreaks. The growing challenge of antimicrobial resistance (AMR) and recurring public health emergencies further increased reliance on APIs for anti-infective therapies, making this segment a cornerstone of global healthcare demand.
Active Pharmaceutical Ingredients Market, By End User
In 2024, the pharmaceutical and biotechnology industry segment accounted for the major share in the market owing to its extensive utilization of APIs in drug discovery, clinical development, and large-scale commercial manufacturing. This dominance is further supported by the expanding pipeline of innovative biologics, biosimilars, and complex small-molecule therapies, as well as rising R&D investments and outsourcing trends to API/CDMO suppliers to meet growing global demand.
REGION
Asia Pacific to be fastest-growing region in global active pharmaceutical ingredients market during forecast period
The Asia Pacific active pharmaceutical ingredients market is expected to register the highest CAGR during the forecast period, driven by strong government initiatives to boost domestic API production, cost advantages in manufacturing, and increasing investments under schemes such as India’s Production-Linked Incentive (PLI). The region benefits from a large pool of skilled chemists, expanding pharmaceutical exports, rising prevalence of chronic diseases, and growing demand from generic and innovative drug pipelines. China and India continue to lead global API supply, while emerging hubs in South Korea and Southeast Asia are strengthening the region’s role as a critical engine of API market growth.
Active Pharmaceutical Ingredient Market: COMPANY EVALUATION MATRIX
In the active pharmaceutical ingredients (API) market matrix, Pfizer (Star) leads with a strong market share and broad API footprint, backed by its global scale, diversified therapeutic portfolio, and integrated manufacturing capabilities that ensure a reliable supply of both innovative and generic drugs. EUROAPI (Emerging Leader) is gaining traction with its specialized API portfolio in corticosteroids, hormones, and antibiotics, while also expanding its merchant supply business beyond Sanofi. Through its Focus-27 strategy, EUROAPI is strengthening competitiveness by streamlining operations and investing in differentiated, high-value APIs.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Pfizer Inc. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Divi’s Laboratories Limited (India)
- Sandoz Group AG (Switzerland)
- SK Inc. (South Korea)
- EUROAPI (France)
- Dr. Reddy’s Laboratories Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Cipla (India)
- Aurobindo Pharma (India)
- Evonik Industries AG (Germany)
- Hikma Pharmaceuticals plc (UK)
- BASF SE (Germany)
- Alembic Pharmaceuticals Limited (India)
- Siegfried Holding AG (Switzerland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 144.20 Billion |
| Market Forecast in 2030 (value) | USD 198.39 Billion |
| Growth Rate | CAGR of 6.6% from 2025–2030 |
| Years Considered | 2023–2030 |
| Base Year | 2024 |
| Forecast Period | 2025–2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends. |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: Active Pharmaceutical Ingredient Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product-specific |
|
Identify high-growth API categories (e.g., GLP-1, oncology, anti-infectives), prioritize investments in differentiated, high-margin APIs |
| Therapy-specific (indication focus) | API demand outlook by therapy: oncology, cardiovascular, CNS, metabolic disorders, anti-infectives | Highlight therapy areas with rising API demand and guide focus toward high-potential CDMO/merchant opportunities |
| Geographic (market entry & access) |
|
Accelerate market-entry and sourcing strategies; Enhance regulatory, pricing, and supply chain readiness |
| Company profiles | Profiles of merchant vs. captive API players: portfolio mix, expansions, partnerships, deals | Support quick diligence for partnerships and M&A, assess competitive positioning |
RECENT DEVELOPMENTS
- December 2024 : Novo Holdings announced an agreement to acquire Catalent for USD 16.5 billion. While Catalent is a diversified CDMO, APIs and drug substance manufacturing form a key part of its portfolio. The deal strengthens the control of Novo Holdings over the drug substance value chain, particularly in biologics APIs, and reflects ongoing consolidation in the CDMO/API sector.
- July 2024 : AbbVie committed USD 195 million to expand its North Chicago facility, focusing on API production for immunology, neuroscience, and oncology therapies. The investment is part of AbbVie’s strategy to reinforce US-based manufacturing and reduce reliance on imports, aligning with reshoring initiatives and government incentives. It underscores big pharma’s push to secure critical API supply near end markets.
- June 2024 : Siegfried Holding AG acquired a drug development and manufacturing site in Grafton, Wisconsin, from Curia Global. The acquisition expands Siegfried’s early-phase API and drug substance CDMO capabilities in the US, while enhancing its geographic footprint. This move highlights the strategy of European API/CDMO players to strengthen their presence in North America, where early-stage development demand is accelerating.
- February 2024 : Suven Pharmaceuticals merged with Cohance Lifesciences, backed by TA Associates, through a share-swap arrangement. The deal significantly strengthens the API and CDMO portfolio of Suven by integrating Cohance’s expertise in oncology APIs and antibody-drug conjugate (ADC) payloads, positioning the combined entity as a more competitive player in high-growth therapeutic areas. This consolidation reflects the broader industry trend of Indian API and CDMO companies scaling capabilities in complex and high-value molecules to serve global demand.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
49
2
RESEARCH METHODOLOGY
54
3
EXECUTIVE SUMMARY
68
4
PREMIUM INSIGHTS
76
5
MARKET OVERVIEW
82
5.1
INTRODUCTION
82
5.2
MARKET DYNAMICS
82
5.2.1
DRIVERS
84
5.2.1.1
SURGE IN DEMAND FOR COMPLEX APIS
84
5.2.1.2
FAVORABLE GOVERNMENT INCENTIVES AND SUPPLY CHAIN RESHORING
84
5.2.1.3
INCREASING ADOPTION OF CONTINUOUS MANUFACTURING AND DIGITAL PROCESS CONTROLS
85
5.2.1.4
RAPID GROWTH OF ONCOLOGY AND RARE DISEASE PIPELINES
86
5.2.2
RESTRAINTS
88
5.2.2.1
TIGHTENING REGULATORY REQUIREMENTS FOR NITROSAMINE AND IMPURITY CONTROLS
88
5.2.2.2
HIGH PRODUCTION COSTS IN US AND EUROPE-BASED FACILITIES
89
5.2.2.3
PRICE PRESSURE FROM GENERIC TENDERS AND SINGLE-WINNER PROCUREMENT POLICIES
89
5.2.3
OPPORTUNITIES
89
5.2.3.1
GROWING EMPHASIS ON SUPPLY RESILIENCE AND SECURITY OF CRITICAL MEDICINE MANUFACTURING
89
5.2.3.2
CHINA-PLUS-ONE STRATEGY
90
5.2.3.3
INCREASING ADOPTION OF INTEGRATED CDMO SERVICE MODELS
90
5.2.4
CHALLENGES
91
5.2.4.1
CAPITAL-INTENSIVE INVESTMENTS FOR HIGH CONTAINMENT AND ADVANCED FACILITIES
91
5.2.4.2
QUALITY FAILURES AND SITE SHUTDOWNS
91
5.2.4.3
SUPPLY CHAIN CONCENTRATION RISK
91
5.2.4.4
GEOPOLITICAL TENSIONS AND TRADE RESTRICTIONS
92
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
92
5.4
PRICING ANALYSIS
93
5.4.1
INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
93
5.4.2
INDICATIVE PRICING ANALYSIS, BY REGION, 2024
95
5.5
TECHNOLOGY ANALYSIS
96
5.5.1
KEY TECHNOLOGIES
96
5.5.1.1
CONTINUOUS MANUFACTURING
96
5.5.1.2
ADVANCED ANALYTICAL TECHNIQUES
97
5.5.1.3
BIOCATALYSIS
97
5.5.2
COMPLEMENTARY TECHNOLOGIES
97
5.5.2.1
DATA ANALYTICS AND DIGITALIZATION
97
5.5.2.2
PERSONALIZED MEDICINES AND CUSTOM SYNTHESIS
97
5.5.2.3
SUPERCRITICAL FLUID TECHNOLOGY
98
5.5.3
ADJACENT TECHNOLOGIES
98
5.5.3.1
SUPPLY CHAIN VISIBILITY AND BLOCKCHAIN
98
5.5.3.2
3D PRINTING
98
5.5.3.3
NANOTECHNOLOGY
99
5.6
SUPPLY CHAIN ANALYSIS
99
5.7
VALUE CHAIN ANALYSIS
100
5.7.1
RESEARCH & DEVELOPMENT (VALUE ADDITION: 30–35%)
101
5.7.2
CLINICAL TRIALS & REGULATORY APPROVALS (VALUE ADDITION: 50–70%)
102
5.7.3
MANUFACTURING (VALUE ADDITION: 70–80%)
102
5.7.4
MARKETING & COMMERCIALIZATION (VALUE ADDITION: 80–100%)
102
5.8
ECOSYSTEM ANALYSIS
102
5.9
KEY CONFERENCES & EVENTS
104
5.10
REGULATORY ANALYSIS
105
5.10.1
REGULATORY SCENARIO
106
5.10.1.1
NORTH AMERICA
106
5.10.1.2
EUROPE
106
5.10.1.3
ASIA PACIFIC
107
5.10.1.4
LATIN AMERICA
107
5.10.1.5
MIDDLE EAST & AFRICA
107
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
108
5.11
PORTER’S FIVE FORCES ANALYSIS
110
5.11.1
THREAT OF NEW ENTRANTS
112
5.11.2
THREAT OF SUBSTITUTES
112
5.11.3
BARGAINING POWER OF SUPPLIERS
112
5.11.4
BARGAINING POWER OF BUYERS
112
5.11.5
INTENSITY OF COMPETITIVE RIVALRY
112
5.12
KEY STAKEHOLDERS AND BUYING CRITERIA
113
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
113
5.12.2
KEY BUYING CRITERIA
114
5.13
CASE STUDY ANALYSIS
115
5.14
MACROECONOMICS INDICATORS
116
5.14.1
HEALTHCARE EXPENDITURE TRENDS
116
5.14.2
GLOBAL CANCER BURDEN
117
5.15
PATENT ANALYSIS
118
5.15.1
LIST OF PATENTS
120
5.16
UNMET NEEDS AND WHITE SPACES
120
5.17
TRADE DATA
121
5.17.1
IMPORT DATA FOR HS CODE–2941
121
5.17.2
EXPORT DATA FOR HS CODE–2941
124
5.18
INVESTMENT AND FUNDING SCENARIO
127
5.19
MANUFACTURING SITES AND CAPACITY EXPANSION OF KEY API SUPPLIERS
128
5.20
IMPACT OF AI/GEN AI ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
131
5.20.1
INTRODUCTION
131
5.20.2
IMPACT AND MARKET POTENTIAL OF ARTIFICIAL INTELLIGENCE IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
131
5.20.3
AI USE CASES
132
5.20.4
FUTURE OF GENERATIVE AI IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ECOSYSTEM
133
5.21
IMPACT OF US TARIFF ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
134
5.21.1
INTRODUCTION
134
5.21.2
KEY TARIFF RATES
134
5.21.3
PRICE IMPACT ANALYSIS
135
5.21.4
IMPACT ON COUNTRY/REGION
136
5.21.4.1
NORTH AMERICA
136
5.21.4.2
EUROPE
136
5.21.4.3
ASIA PACIFIC
136
5.21.5
IMPACT ON END-USE INDUSTRIES
136
5.21.5.1
PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
136
5.21.5.2
CONTRACT RESEARCH ORGANIZATIONS (CROS)
137
5.21.5.3
CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
137
6
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
138
6.1
INTRODUCTION
139
6.2
ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT)
139
6.3
INNOVATIVE APIS
140
6.3.1
INCREASING REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO FACILITATE GROWTH
140
6.4
GENERIC APIS
144
6.4.1
GROWING FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET
144
7
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY
148
7.1
INTRODUCTION
149
7.2
ACTIVE PHARMACEUTICAL INGREDIENTS, BY POTENCY (CAPTIVE AND MERCHANT)
149
7.3
TRADITIONAL APIS
150
7.3.1
INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO AUGMENT GROWTH
150
7.4
HIGHLY POTENT APIS
154
7.4.1
SYNTHETIC
158
7.4.1.1
EVOLVING TARGETED ONCOLOGY THERAPIES TO STIMULATE GROWTH
158
7.4.2
BIOLOGICS
161
7.4.2.1
ROBUST PRODUCT PIPELINE TO ENCOURAGE GROWTH
161
8
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS
165
8.1
INTRODUCTION
166
8.2
ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT)
166
8.3
SYNTHETIC APIS
167
8.3.1
INNOVATIVE SYNTHETIC APIS
171
8.3.1.1
HIGH VALUE OF INNOVATIVE APIS TO DRIVE MARKET
171
8.3.2
GENERIC SYNTHETIC APIS
175
8.3.2.1
INCREASING NEED FOR GENERIC MEDICINES TO CONTRIBUTE TO GROWTH
175
8.4
BIOTECH APIS
178
8.4.1
BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
182
8.4.1.1
INNOVATIVE BIOTECH APIS
182
8.4.1.2
GENERIC BIOTECH APIS
186
8.4.2
BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
190
8.4.2.1
MONOCLONAL ANTIBODIES
190
8.4.2.2
HORMONES AND GROWTH FACTORS
194
8.4.2.3
FUSION PROTEINS
197
8.4.2.4
CYTOKINES
200
8.4.2.5
THERAPEUTIC ENZYMES
203
8.4.2.6
BLOOD FACTORS AND ANTI-COAGULANTS
206
8.4.2.7
RECOMBINANT VACCINES
209
8.4.3
BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM
212
8.4.3.1
MAMMALIAN EXPRESSION SYSTEMS
213
8.4.3.2
MICROBIAL EXPRESSION SYSTEMS
217
8.4.3.3
YEAST EXPRESSION SYSTEMS
220
8.4.3.4
INSECT EXPRESSION SYSTEMS
224
8.4.3.5
OTHER EXPRESSION SYSTEMS
228
9
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG
231
9.1
INTRODUCTION
232
9.2
ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF DRUG (CAPTIVE AND MERCHANT)
232
9.3
PRESCRIPTION DRUGS
233
9.3.1
INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT GROWTH
233
9.4
OVER-THE-COUNTER DRUGS
237
9.4.1
RISING AWARENESS OF PRECAUTIONARY CARE AND HEALTH CONCERNS TO SPUR GROWTH
237
10
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION
241
10.1
INTRODUCTION
242
10.2
ACTIVE PHARMACEUTICAL INGREDIENTS, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT)
242
10.3
COMMUNICABLE DISEASES
244
10.3.1
INCREASING INVESTMENTS IN DEVELOPING NEW ANTIBIOTICS, ANTIVIRALS, ANTIFUNGALS, AND VACCINES TO AID GROWTH
244
10.4
ONCOLOGY
247
10.4.1
GROWING NUMBER OF FDA APPROVALS TO DRIVE MARKET
247
10.5
DIABETES
251
10.5.1
RISING ADVANCEMENTS IN TREATMENT OPTIONS TO EXPEDITE GROWTH
251
10.6
CARDIOVASCULAR DISEASES
255
10.6.1
INCREASING ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS TO PROMOTE GROWTH
255
10.7
RESPIRATORY DISEASES
258
10.7.1
INCREASING BURDEN OF RESPIRATORY DISORDERS TO BOLSTER GROWTH
258
10.8
PAIN MANAGEMENT
262
10.8.1
RISING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO BOLSTER GROWTH
262
10.9
OTHER THERAPEUTIC APPLICATIONS
265
11
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER
269
11.1
INTRODUCTION
270
11.2
ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER (CAPTIVE AND MERCHANT)
270
11.3
PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
272
11.3.1
RISE IN NEED OF NOVEL TREATMENTS TO EXPEDITE GROWTH
272
11.4
CONTRACT RESEARCH ORGANIZATIONS
275
11.4.1
INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT GROWTH
275
11.5
CONTRACT MANUFACTURING ORGANIZATIONS
279
11.5.1
GROWING FOCUS ON BETTER QUALITY AND REGULATORY COMPLIANCE TO DRIVE MARKET
279
11.6
OTHER END USERS
282
12
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION
286
12.1
INTRODUCTION
287
12.2
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (CAPTIVE AND MERCHANT)
287
12.3
NORTH AMERICA
289
12.3.1
MACROECONOMIC ANALYSIS OF NORTH AMERICA
290
12.3.2
US
296
12.3.2.1
HIGH CLINICAL TRIAL & DRUG DISCOVERY ACTIVITY AND EFFICIENT REGULATORY ENVIRONMENT TO EXPEDITE GROWTH
296
12.3.3
CANADA
301
12.3.3.1
FAVORABLE GOVERNMENT SUPPORT AND STRONG PRODUCT PIPELINE TO SUSTAIN GROWTH
301
12.4
EUROPE
306
12.4.1
MACROECONOMIC ANALYSIS OF EUROPE
307
12.4.2
GERMANY
313
12.4.2.1
HIGH HEALTHCARE EXPENDITURE AND ADVANCED R&D FACILITIES TO DRIVE MARKET
313
12.4.3
UK
318
12.4.3.1
RISING GOVERNMENT INVESTMENTS AND GROWING FOCUS ON PERSONALIZED TREATMENT TO FUEL MARKET
318
12.4.4
FRANCE
323
12.4.4.1
INCREASED FOCUS ON DOMESTIC MANUFACTURING TO PROMOTE GROWTH
323
12.4.5
ITALY
328
12.4.5.1
RISING COMMERCIAL DRUG DEVELOPMENT TO FAVOR GROWTH
328
12.4.6
SPAIN
333
12.4.6.1
INCREASE IN GENERIC DRUG MANUFACTURING CAPACITY TO PROPEL MARKET
333
12.4.7
HUNGARY
338
12.4.7.1
INCREASING MANUFACTURING ACTIVITIES IN PHARMACEUTICAL SECTOR TO DRIVE MARKET
338
12.4.8
REST OF EUROPE
343
12.5
ASIA PACIFIC
348
12.5.1
MACROECONOMIC ANALYSIS OF ASIA PACIFIC
349
12.5.2
CHINA
355
12.5.2.1
RISE IN GOVERNMENT POLICIES TO INCREASE MEDICINE ACCESS AND AFFORDABILITY TO SUPPORT GROWTH
355
12.5.3
JAPAN
360
12.5.3.1
GROWING GERIATRIC POPULATION TO BOOST MARKET
360
12.5.4
INDIA
365
12.5.4.1
INCREASING R&D ACTIVITIES AND RISING GOVERNMENT FUNDING INITIATIVES TO FAVOR GROWTH
365
12.5.5
SOUTH KOREA
370
12.5.5.1
RISING ANNUAL DRUG EXPORTS TO DRIVE MARKET
370
12.5.6
AUSTRALIA
375
12.5.6.1
INCREASING DEMAND FOR INNOVATIVE APIS TO PROPEL MARKET
375
12.5.7
REST OF ASIA PACIFIC
380
12.6
LATIN AMERICA
385
12.6.1
LATIN AMERICA: MACROECONOMIC ANALYSIS
385
12.6.2
BRAZIL
391
12.6.2.1
INCREASED GOVERNMENT INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
391
12.6.3
MEXICO
396
12.6.3.1
RISING INVESTMENTS BY FOREIGN FIRMS TO SUPPORT MARKET GROWTH
396
12.6.4
REST OF LATIN AMERICA
401
12.7
MIDDLE EAST
406
12.7.1
MACROECONOMIC ANALYSIS OF MIDDLE EAST
406
12.7.2
ISRAEL
412
12.7.2.1
HIGHLY EDUCATED WORKFORCE AND STRONG CULTURE OF INNOVATIONS TO SUPPORT GROWTH
412
12.7.3
GCC COUNTRIES
417
12.7.3.1
SAUDI ARABIA
422
12.7.3.2
UAE
427
12.7.3.3
REST OF GCC COUNTRIES
432
12.7.4
REST OF MIDDLE EAST
437
12.8
AFRICA
442
12.8.1
GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET
442
12.8.2
MACROECONOMIC OUTLOOK FOR AFRICA
442
13
COMPETITIVE LANDSCAPE
449
13.1
INTRODUCTION
449
13.2
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
449
13.3
REVENUE ANALYSIS, 2022–2024
451
13.4
MARKET SHARE ANALYSIS, 2024
452
13.5
COMPANY VALUATION AND FINANCIAL METRICS
454
13.5.1
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
455
13.6
BRAND/PRODUCT COMPARISON
456
13.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
458
13.7.1
STARS
458
13.7.2
EMERGING LEADERS
458
13.7.3
PERVASIVE PLAYERS
458
13.7.4
PARTICIPANTS
458
13.7.5
COMPETITIVE BENCHMARKING, 2024
460
13.7.5.1
COMPANY FOOTPRINT
460
13.7.5.2
REGION FOOTPRINT
461
13.7.5.3
TYPE FOOTPRINT
462
13.7.5.4
POTENCY FOOTPRINT
463
13.7.5.5
THERAPEUTIC APPLICATION FOOTPRINT
464
13.8
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
466
13.8.1
PROGRESSIVE COMPANIES
466
13.8.2
RESPONSIVE COMPANIES
466
13.8.3
DYNAMIC COMPANIES
466
13.8.4
STARTING BLOCKS
466
13.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
468
13.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
468
13.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
470
13.9
COMPETITIVE SCENARIO
471
13.9.1
PRODUCT APPROVALS
471
13.9.2
DEALS
471
13.9.3
EXPANSIONS
473
14
COMPANY PROFILES
476
14.1
KEY PLAYERS
476
14.1.1
PFIZER INC.
476
14.1.1.1
BUSINESS OVERVIEW
476
14.1.1.2
PRODUCTS OFFERED
477
14.1.1.3
RECENT DEVELOPMENTS
479
14.1.1.4
MNM VIEW
480
14.1.2
DIVI’S LABORATORIES LIMITED
481
14.1.2.1
BUSINESS OVERVIEW
481
14.1.2.2
PRODUCTS OFFERED
482
14.1.2.3
RECENT DEVELOPMENTS
483
14.1.2.4
MNM VIEW
484
14.1.3
ASYMCHEM INC.
485
14.1.3.1
BUSINESS OVERVIEW
485
14.1.3.2
PRODUCTS OFFERED
486
14.1.3.3
RECENT DEVELOPMENTS
487
14.1.3.4
MNM VIEW
488
14.1.4
CIPLA
489
14.1.4.1
BUSINESS OVERVIEW
489
14.1.4.2
PRODUCTS OFFERED
490
14.1.4.3
RECENT DEVELOPMENTS
492
14.1.4.4
MNM VIEW
492
14.1.5
EVONIK
494
14.1.5.1
BUSINESS OVERVIEW
494
14.1.5.2
PRODUCTS OFFERED
495
14.1.5.3
RECENT DEVELOPMENTS
496
14.1.5.4
MNM VIEW
498
14.1.6
TEVA PHARMACEUTICAL INDUSTRIES LTD.
499
14.1.6.1
BUSINESS OVERVIEW
499
14.1.6.2
PRODUCTS OFFERED
500
14.1.6.3
RECENT DEVELOPMENTS
509
14.1.7
SANDOZ GROUP AG
510
14.1.7.1
BUSINESS OVERVIEW
510
14.1.7.2
PRODUCTS OFFERED
511
14.1.7.3
RECENT DEVELOPMENTS
513
14.1.8
SK INC.
514
14.1.8.1
BUSINESS OVERVIEW
514
14.1.8.2
PRODUCTS OFFERED
515
14.1.8.3
RECENT DEVELOPMENTS
516
14.1.9
MERCK KGAA
518
14.1.9.1
BUSINESS OVERVIEW
518
14.1.9.2
PRODUCTS OFFERED
519
14.1.9.3
RECENT DEVELOPMENTS
520
14.1.10
DR. REDDY’S LABORATORIES LTD.
522
14.1.10.1
BUSINESS OVERVIEW
522
14.1.10.2
PRODUCTS OFFERED
523
14.1.10.3
RECENT DEVELOPMENTS
525
14.1.11
SUN PHARMACEUTICAL INDUSTRIES LTD.
526
14.1.11.1
BUSINESS OVERVIEW
526
14.1.11.2
PRODUCTS OFFERED
527
14.1.11.3
RECENT DEVELOPMENTS
529
14.1.12
AUROBINDO PHARMA LIMITED
530
14.1.12.1
BUSINESS OVERVIEW
530
14.1.12.2
PRODUCTS OFFERED
531
14.1.12.3
RECENT DEVELOPMENTS
532
14.1.13
HIKMA PHARMACEUTICALS PLC
533
14.1.13.1
BUSINESS OVERVIEW
533
14.1.13.2
PRODUCTS OFFERED
534
14.1.13.3
RECENT DEVELOPMENTS
535
14.1.14
BASF
536
14.1.14.1
BUSINESS OVERVIEW
536
14.1.14.2
PRODUCTS OFFERED
537
14.1.15
ALEMBIC PHARMACEUTICALS LIMITED
539
14.1.15.1
BUSINESS OVERVIEW
539
14.1.15.2
PRODUCTS OFFERED
540
14.1.15.3
RECENT DEVELOPMENTS
541
14.1.16
SIEGFRIED HOLDING AG
542
14.1.16.1
BUSINESS OVERVIEW
542
14.1.16.2
PRODUCTS OFFERED
543
14.1.16.3
RECENT DEVELOPMENTS
544
14.1.17
EUROAPI
546
14.1.17.1
BUSINESS OVERVIEW
546
14.1.17.2
PRODUCTS OFFERED
547
14.1.17.3
RECENT DEVELOPMENTS
547
14.1.18
BACHEM
548
14.1.18.1
BUSINESS OVERVIEW
548
14.1.18.2
PRODUCTS OFFERED
549
14.1.19
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
551
14.1.19.1
BUSINESS OVERVIEW
551
14.1.19.2
PRODUCTS OFFERED
551
14.1.20
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
553
14.1.20.1
BUSINESS OVERVIEW
553
14.1.20.2
PRODUCTS OFFERED
553
14.2
OTHER PLAYERS
555
14.2.1
POLYPEPTIDE GROUP
555
14.2.2
GRANULES INDIA
556
14.2.3
CORDEN PHARMA
557
14.2.4
RECIPHARM
558
14.2.5
ABURAIHAN PHARMACEUTICAL COMPANY
559
14.2.6
CURIA GLOBAL, INC.
560
14.2.7
CAMBREX CORPORATION
561
14.2.8
API PHARMA TECH
562
14.2.9
SREEPATHI PHARMACEUTICALS LIMITED
563
14.2.10
SHILPA MEDICARE LIMITED
564
14.2.11
NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.
565
14.2.12
HOVIONE
566
14.2.13
CHEMCON GMBH
567
14.2.14
PHARCO PHARMACEUTICALS
567
14.2.15
SAMBI PHARMA PVT. LTD.
568
15
DISCUSSION GUIDE
569
15.1
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
574
15.2
CUSTOMIZATION OPTIONS
576
15.3
RELATED REPORTS
576
15.4
AUTHOR DETAILS
577
LIST OF TABLES
TABLE 1
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCLUSIONS AND EXCLUSIONS
50
TABLE 2
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
64
TABLE 3
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RISK ANALYSIS
67
TABLE 4
PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
80
TABLE 5
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
83
TABLE 6
ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVAL, 2024
87
TABLE 7
EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE CERTIFICATE OF SUITABILITY TO MONOGRAPHS OF EUROPEAN PHARMACOPOEIA (EDQM CEP) CERTIFICATION ACTIVITY, 2024
88
TABLE 8
INDICATIVE PRICING OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER, 2024 (USD)
94
TABLE 9
INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2024 (USD)
95
TABLE 10
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ROLE IN ECOSYSTEM
103
TABLE 11
ACTIVE PHARMACEUTICAL INGREDIENTS: KEY CONFERENCES & EVENTS, 2025–2026
104
TABLE 12
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
108
TABLE 13
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
108
TABLE 14
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
109
TABLE 15
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
110
TABLE 16
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
110
TABLE 17
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES
111
TABLE 18
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
113
TABLE 19
BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER
114
TABLE 20
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CASE STUDY ANALYSIS
115
TABLE 21
HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP)
116
TABLE 22
CANCER INCIDENCE, BY REGION, 2022
118
TABLE 23
NUMBER OF PATENTS FILED IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2014–2024
119
TABLE 24
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: LIST OF PATENTS, 2023
120
TABLE 25
IMPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VALUE (USD)
121
TABLE 26
IMPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VOLUME (TONS)
121
TABLE 27
IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VALUE (USD)
122
TABLE 28
IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VOLUME (TONS)
122
TABLE 29
IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONES, HS CODE–2937, 2020-2024, VALUE (USD)
123
TABLE 30
IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONES, HS CODE–2934, 2020-2024, VOLUME (TON
123
TABLE 31
EXPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VALUE (USD)
124
TABLE 32
EXPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VOLUME (TONS)
124
TABLE 33
EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VALUE (USD)
125
TABLE 34
EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VOLUME (TONS)
125
TABLE 35
EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONE, HS CODE–2934, 2020-2024, VALUE (USD)
126
TABLE 36
EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONES, HS CODE–2934, 2020-2024, VOLUME (TON
126
TABLE 37
MANUFACTURING SITES OF KEY API SUPPLIERS
128
TABLE 38
LIST OF SITE EXPANSIONS FOR API MANUFACTURERS, 2023–2025
130
TABLE 39
KEY COMPANIES IMPLEMENTING AI
133
TABLE 40
US ADJUSTED RECIPROCAL TARIFF RATES
134
TABLE 41
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
139
TABLE 42
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)
139
TABLE 43
CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
140
TABLE 44
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY REGION, 2023–2030 (USD BILLION)
141
TABLE 45
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)
141
TABLE 46
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)
142
TABLE 47
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)
142
TABLE 48
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)
143
TABLE 49
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)
143
TABLE 50
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)
143
TABLE 51
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY REGION, 2023–2030 (USD BILLION)
144
TABLE 52
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
145
TABLE 53
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
145
TABLE 54
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
146
TABLE 55
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
146
TABLE 56
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
146
TABLE 57
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
147
TABLE 58
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
149
TABLE 59
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)
149
TABLE 60
CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
150
TABLE 61
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY REGION, 2023–2030 (USD BILLION)
151
TABLE 62
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)
151
TABLE 63
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)
152
TABLE 64
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)
152
TABLE 65
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)
153
TABLE 66
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)
153
TABLE 67
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)
153
TABLE 68
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY TYPE, 2023–2030 (USD BILLION)
154
TABLE 69
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY REGION, 2023–2030 (USD BILLION)
155
TABLE 70
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)
155
TABLE 71
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)
156
TABLE 72
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)
156
TABLE 73
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)
157
TABLE 74
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)
157
TABLE 75
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)
157
TABLE 76
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION)
158
TABLE 77
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
159
TABLE 78
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
159
TABLE 79
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
160
TABLE 80
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
160
TABLE 81
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
160
TABLE 82
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
161
TABLE 83
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD BILLION)
162
TABLE 84
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)
162
TABLE 85
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)
163
TABLE 86
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)
163
TABLE 87
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)
164
TABLE 88
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)
164
TABLE 89
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)
164
TABLE 90
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 (USD BILLION)
166
TABLE 91
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)
166
TABLE 92
CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 (USD BILLION)
167
TABLE 93
SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2023–2030 (USD BILLION)
168
TABLE 94
NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
168
TABLE 95
EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
169
TABLE 96
ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
169
TABLE 97
LATIN AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
170
TABLE 98
MIDDLE EAST: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
170
TABLE 99
GCC COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
170
TABLE 100
SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
171
TABLE 101
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION)
172
TABLE 102
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
172
TABLE 103
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
173
TABLE 104
ASIA PACIFIC: INACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
173
TABLE 105
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
174
TABLE 106
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
174
TABLE 107
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
174
TABLE 108
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION)
175
TABLE 109
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
176
TABLE 110
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
176
TABLE 111
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
177
TABLE 112
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
177
TABLE 113
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
178
TABLE 114
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)
178
TABLE 115
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION)
179
TABLE 116
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
179
TABLE 117
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
180
TABLE 118
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
180
TABLE 119
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
181
TABLE 120
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
181
TABLE 121
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
181
TABLE 122
BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
182
TABLE 123
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION)
183
TABLE 124
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
183
TABLE 125
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
184
TABLE 126
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
184
TABLE 127
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
185
TABLE 128
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
185
TABLE 129
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
185
TABLE 130
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION)
187
TABLE 131
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
187
TABLE 132
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
188
TABLE 133
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
188
TABLE 134
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
189
TABLE 135
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
189
TABLE 136
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)
189
TABLE 137
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
190
TABLE 138
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
191
TABLE 139
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
191
TABLE 140
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
192
TABLE 141
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
192
TABLE 142
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
193
TABLE 143
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
193
TABLE 144
GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
193
TABLE 145
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY REGION, 2023–2030 (USD BILLION)
194
TABLE 146
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)
194
TABLE 147
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)
195
TABLE 148
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)
195
TABLE 149
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)
196
TABLE 150
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)
196
TABLE 151
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)
196
TABLE 152
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2023–2030 (USD BILLION)
197
TABLE 153
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
197
TABLE 154
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
198
TABLE 155
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
198
TABLE 156
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
199
TABLE 157
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
199
TABLE 158
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
199
TABLE 159
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2023–2030 (USD BILLION)
200
TABLE 160
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)
200
TABLE 161
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)
201
TABLE 162
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)
201
TABLE 163
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)
202
TABLE 164
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)
202
TABLE 165
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)
202
TABLE 166
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2023–2030 (USD BILLION)
203
TABLE 167
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)
203
TABLE 168
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)
204
TABLE 169
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)
204
TABLE 170
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)
205
TABLE 171
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)
205
TABLE 172
GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)
205
TABLE 173
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY REGION, 2023–2030 (USD BILLION)
206
TABLE 174
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)
206
TABLE 175
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)
207
TABLE 176
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)
207
TABLE 177
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)
208
TABLE 178
MIDDLE EAST: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)
208
TABLE 179
GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)
208
TABLE 180
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2023–2030 (USD BILLION)
209
TABLE 181
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
210
TABLE 182
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
210
TABLE 183
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
211
TABLE 184
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
211
TABLE 185
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
212
TABLE 186
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
212
TABLE 187
BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
213
TABLE 188
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)
214
TABLE 189
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
214
TABLE 190
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
215
TABLE 191
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
215
TABLE 192
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
216
TABLE 193
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
216
TABLE 194
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
216
TABLE 195
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)
217
TABLE 196
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
218
TABLE 197
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
218
TABLE 198
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
219
TABLE 199
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
219
TABLE 200
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
220
TABLE 201
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
220
TABLE 202
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)
221
TABLE 203
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
221
TABLE 204
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
222
TABLE 205
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
222
TABLE 206
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
223
TABLE 207
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
223
TABLE 208
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
223
TABLE 209
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)
225
TABLE 210
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
225
TABLE 211
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
226
TABLE 212
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
226
TABLE 213
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
227
TABLE 214
MIDDLE EAST: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
227
TABLE 215
GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
227
TABLE 216
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)
228
TABLE 217
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
228
TABLE 218
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
229
TABLE 219
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
229
TABLE 220
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
230
TABLE 221
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
230
TABLE 222
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)
230
TABLE 223
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
232
TABLE 224
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)
232
TABLE 225
CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
233
TABLE 226
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2023–2030 (USD BILLION)
234
TABLE 227
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
234
TABLE 228
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
235
TABLE 229
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
235
TABLE 230
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
236
TABLE 231
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
236
TABLE 232
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
236
TABLE 233
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2023–2030 (USD BILLION)
237
TABLE 234
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
238
TABLE 235
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER- THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
238
TABLE 236
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
239
TABLE 237
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
239
TABLE 238
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
239
TABLE 239
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)
240
TABLE 240
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
242
TABLE 241
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)
243
TABLE 242
CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
243
TABLE 243
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2023–2030 (USD BILLION)
244
TABLE 244
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
245
TABLE 245
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
245
TABLE 246
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
246
TABLE 247
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
246
TABLE 248
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
247
TABLE 249
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
247
TABLE 250
LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER
248
TABLE 251
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD BILLION)
248
TABLE 252
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
249
TABLE 253
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
249
TABLE 254
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
250
TABLE 255
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
250
TABLE 256
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
250
TABLE 257
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
251
TABLE 258
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2023–2030 (USD BILLION)
252
TABLE 259
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)
252
TABLE 260
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)
253
TABLE 261
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)
253
TABLE 262
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)
254
TABLE 263
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)
254
TABLE 264
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)
254
TABLE 265
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD BILLION)
255
TABLE 266
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
256
TABLE 267
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
256
TABLE 268
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
257
TABLE 269
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
257
TABLE 270
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
257
TABLE 271
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
258
TABLE 272
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2030 (USD BILLION)
259
TABLE 273
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
259
TABLE 274
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
260
TABLE 275
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
260
TABLE 276
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
261
TABLE 277
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
261
TABLE 278
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
261
TABLE 279
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD BILLION)
262
TABLE 280
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
263
TABLE 281
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
263
TABLE 282
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
264
TABLE 283
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
264
TABLE 284
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
264
TABLE 285
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
265
TABLE 286
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD BILLION)
266
TABLE 287
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
266
TABLE 288
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
267
TABLE 289
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
267
TABLE 290
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
268
TABLE 291
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
268
TABLE 292
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
268
TABLE 293
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
270
TABLE 294
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)
271
TABLE 295
CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
271
TABLE 296
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY REGION, 2023–2030 (USD BILLION)
272
TABLE 297
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION)
273
TABLE 298
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION)
273
TABLE 299
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION)
274
TABLE 300
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION)
274
TABLE 301
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION)
274
TABLE 302
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION)
275
TABLE 303
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD BILLION)
276
TABLE 304
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
276
TABLE 305
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
277
TABLE 306
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
277
TABLE 307
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
278
TABLE 308
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
278
TABLE 309
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
278
TABLE 310
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2023–2030 (USD BILLION)
279
TABLE 311
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
280
TABLE 312
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
280
TABLE 313
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
281
TABLE 314
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
281
TABLE 315
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
281
TABLE 316
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
282
TABLE 317
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
283
TABLE 318
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
283
TABLE 319
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
284
TABLE 320
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
284
TABLE 321
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
285
TABLE 322
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
285
TABLE 323
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
285
TABLE 324
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2023–2030 (USD BILLION)
287
TABLE 325
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)
288
TABLE 326
CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2023–2030 (USD BILLION)
288
TABLE 327
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
290
TABLE 328
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
291
TABLE 329
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
291
TABLE 330
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
291
TABLE 331
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
292
TABLE 332
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
292
TABLE 333
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
292
TABLE 334
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
293
TABLE 335
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
293
TABLE 336
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
294
TABLE 337
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
294
TABLE 338
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
295
TABLE 339
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
295
TABLE 340
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
296
TABLE 341
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
297
TABLE 342
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
297
TABLE 343
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
297
TABLE 344
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
298
TABLE 345
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
298
TABLE 346
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
299
TABLE 347
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
299
TABLE 348
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
300
TABLE 349
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
300
TABLE 350
US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
301
TABLE 351
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
302
TABLE 352
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
302
TABLE 353
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
302
TABLE 354
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
303
TABLE 355
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
303
TABLE 356
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
303
TABLE 357
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
304
TABLE 358
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
304
TABLE 359
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
305
TABLE 360
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
305
TABLE 361
CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
306
TABLE 362
EUROPE: KEY MACROECONOMIC INDICATORS
307
TABLE 363
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
308
TABLE 364
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
308
TABLE 365
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
308
TABLE 366
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
309
TABLE 367
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
309
TABLE 368
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
309
TABLE 369
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
310
TABLE 370
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
310
TABLE 371
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
311
TABLE 372
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
311
TABLE 373
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
312
TABLE 374
EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
312
TABLE 375
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
313
TABLE 376
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
314
TABLE 377
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
314
TABLE 378
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
314
TABLE 379
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
315
TABLE 380
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
315
TABLE 381
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
316
TABLE 382
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
316
TABLE 383
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
317
TABLE 384
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
317
TABLE 385
GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
318
TABLE 386
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
319
TABLE 387
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
319
TABLE 388
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
319
TABLE 389
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
320
TABLE 390
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
320
TABLE 391
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
320
TABLE 392
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
321
TABLE 393
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
321
TABLE 394
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
322
TABLE 395
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
322
TABLE 396
UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
323
TABLE 397
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
324
TABLE 398
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
324
TABLE 399
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
324
TABLE 400
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
325
TABLE 401
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
325
TABLE 402
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
325
TABLE 403
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
326
TABLE 404
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
326
TABLE 405
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
327
TABLE 406
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
327
TABLE 407
FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
328
TABLE 408
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
328
TABLE 409
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
329
TABLE 410
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
329
TABLE 411
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
329
TABLE 412
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
330
TABLE 413
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
330
TABLE 414
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
331
TABLE 415
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
331
TABLE 416
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
332
TABLE 417
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
332
TABLE 418
ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
333
TABLE 419
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
334
TABLE 420
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
334
TABLE 421
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
334
TABLE 422
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
335
TABLE 423
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
335
TABLE 424
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
335
TABLE 425
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
336
TABLE 426
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
336
TABLE 427
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
337
TABLE 428
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
337
TABLE 429
SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
338
TABLE 430
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
339
TABLE 431
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
339
TABLE 432
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
339
TABLE 433
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
340
TABLE 434
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
340
TABLE 435
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
340
TABLE 436
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
341
TABLE 437
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
341
TABLE 438
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
342
TABLE 439
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
342
TABLE 440
HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
343
TABLE 441
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
344
TABLE 442
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
344
TABLE 443
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
344
TABLE 444
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
345
TABLE 445
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
345
TABLE 446
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
345
TABLE 447
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
346
TABLE 448
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
346
TABLE 449
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
347
TABLE 450
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
347
TABLE 451
REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
348
TABLE 452
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
350
TABLE 453
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
350
TABLE 454
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
351
TABLE 455
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
351
TABLE 456
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
351
TABLE 457
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
352
TABLE 458
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
352
TABLE 459
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
352
TABLE 460
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
353
TABLE 461
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
353
TABLE 462
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
354
TABLE 463
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
354
TABLE 464
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
355
TABLE 465
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
356
TABLE 466
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
356
TABLE 467
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
356
TABLE 468
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
357
TABLE 469
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
357
TABLE 470
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
357
TABLE 471
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
358
TABLE 472
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
358
TABLE 473
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
359
TABLE 474
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
359
TABLE 475
CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
360
TABLE 476
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
361
TABLE 477
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
361
TABLE 478
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
361
TABLE 479
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
362
TABLE 480
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
362
TABLE 481
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
362
TABLE 482
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
363
TABLE 483
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
363
TABLE 484
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
364
TABLE 485
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
364
TABLE 486
JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
365
TABLE 487
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
366
TABLE 488
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
366
TABLE 489
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
366
TABLE 490
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
367
TABLE 491
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
367
TABLE 492
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
367
TABLE 493
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
368
TABLE 494
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
368
TABLE 495
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
369
TABLE 496
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
369
TABLE 497
INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
370
TABLE 498
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
371
TABLE 499
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
371
TABLE 500
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
371
TABLE 501
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
372
TABLE 502
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
372
TABLE 503
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
372
TABLE 504
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
373
TABLE 505
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
373
TABLE 506
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
374
TABLE 507
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
374
TABLE 508
SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
375
TABLE 509
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
376
TABLE 510
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
376
TABLE 511
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
376
TABLE 512
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
377
TABLE 513
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
377
TABLE 514
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
377
TABLE 515
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
378
TABLE 516
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
378
TABLE 517
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
379
TABLE 518
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
379
TABLE 519
AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
380
TABLE 520
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
381
TABLE 521
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
381
TABLE 522
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
381
TABLE 523
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
382
TABLE 524
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
382
TABLE 525
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
382
TABLE 526
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
383
TABLE 527
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
383
TABLE 528
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
384
TABLE 529
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
384
TABLE 530
REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
385
TABLE 531
LATIN AMERICA: KEY MACRO INDICATORS
386
TABLE 532
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
386
TABLE 533
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
387
TABLE 534
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
387
TABLE 535
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
387
TABLE 536
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
388
TABLE 537
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
388
TABLE 538
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
388
TABLE 539
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
389
TABLE 540
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
389
TABLE 541
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
390
TABLE 542
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
390
TABLE 543
LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
391
TABLE 544
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
392
TABLE 545
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
392
TABLE 546
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
392
TABLE 547
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
393
TABLE 548
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
393
TABLE 549
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
393
TABLE 550
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
394
TABLE 551
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
394
TABLE 552
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
395
TABLE 553
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
395
TABLE 554
BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
396
TABLE 555
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
397
TABLE 556
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
397
TABLE 557
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
397
TABLE 558
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
398
TABLE 559
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
398
TABLE 560
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
398
TABLE 561
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
399
TABLE 562
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
399
TABLE 563
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
400
TABLE 564
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
400
TABLE 565
MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
401
TABLE 566
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
401
TABLE 567
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
402
TABLE 568
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
402
TABLE 569
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
402
TABLE 570
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
403
TABLE 571
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
403
TABLE 572
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
404
TABLE 573
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
404
TABLE 574
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
405
TABLE 575
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
405
TABLE 576
REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
406
TABLE 577
MIDDLE EAST: KEY MACROECONOMIC INDICATORS
407
TABLE 578
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
407
TABLE 579
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
408
TABLE 580
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
408
TABLE 581
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
408
TABLE 582
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
409
TABLE 583
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
409
TABLE 584
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
409
TABLE 585
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
410
TABLE 586
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
410
TABLE 587
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
411
TABLE 588
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
411
TABLE 589
MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
412
TABLE 590
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
412
TABLE 591
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
413
TABLE 592
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
413
TABLE 593
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
413
TABLE 594
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
414
TABLE 595
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
414
TABLE 596
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
415
TABLE 597
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
415
TABLE 598
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
416
TABLE 599
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
416
TABLE 600
ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
417
TABLE 601
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
417
TABLE 602
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
418
TABLE 603
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
418
TABLE 604
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
418
TABLE 605
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
419
TABLE 606
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
419
TABLE 607
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
419
TABLE 608
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
420
TABLE 609
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
420
TABLE 610
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
421
TABLE 611
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
421
TABLE 612
GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
422
TABLE 613
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
423
TABLE 614
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
423
TABLE 615
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
423
TABLE 616
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
424
TABLE 617
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
424
TABLE 618
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
424
TABLE 619
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
425
TABLE 620
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
425
TABLE 621
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
426
TABLE 622
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
426
TABLE 623
SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
427
TABLE 624
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
428
TABLE 625
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
428
TABLE 626
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
428
TABLE 627
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
429
TABLE 628
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
429
TABLE 629
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
429
TABLE 630
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
430
TABLE 631
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
430
TABLE 632
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
431
TABLE 633
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
431
TABLE 634
UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
432
TABLE 635
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
433
TABLE 636
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
433
TABLE 637
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
433
TABLE 638
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
434
TABLE 639
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
434
TABLE 640
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
434
TABLE 641
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
435
TABLE 642
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
435
TABLE 643
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
436
TABLE 644
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
436
TABLE 645
REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
437
TABLE 646
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
438
TABLE 647
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
438
TABLE 648
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
438
TABLE 649
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
439
TABLE 650
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
439
TABLE 651
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
439
TABLE 652
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
440
TABLE 653
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
440
TABLE 654
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
441
TABLE 655
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
441
TABLE 656
REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
442
TABLE 657
AFRICA: KEY MACROECONOMIC INDICATORS
443
TABLE 658
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
443
TABLE 659
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)
444
TABLE 660
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)
444
TABLE 661
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)
444
TABLE 662
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)
445
TABLE 663
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)
445
TABLE 664
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)
446
TABLE 665
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)
446
TABLE 666
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)
447
TABLE 667
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
447
TABLE 668
AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)
448
TABLE 669
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, JANUARY 2022–OCTOBER 2025
450
TABLE 670
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEGREE OF COMPETITION
453
TABLE 671
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: REGION FOOTPRINT
461
TABLE 672
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TYPE FOOTPRINT
462
TABLE 673
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: POTENCY FOOTPRINT
463
TABLE 674
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: THERAPEUTIC APPLICATION FOOTPRINT
464
TABLE 675
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
468
TABLE 676
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY TYPE AND REGION
470
TABLE 677
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PRODUCT APPROVALS, JANUARY 2022–OCTOBER 2025
471
TABLE 678
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEALS, JANUARY 2022–OCTOBER 2025
471
TABLE 679
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: EXPANSIONS, JANUARY 2022–OCTOBER 2025
473
TABLE 680
PFIZER INC.: COMPANY OVERVIEW
476
TABLE 681
PFIZER INC.: PRODUCTS OFFERED
477
TABLE 682
PFIZER INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
479
TABLE 683
DIVI'S LABORATORIES LIMITED: COMPANY OVERVIEW
481
TABLE 684
DIVI'S LABORATORIES LIMITED: PRODUCTS OFFERED
482
TABLE 685
DIVI'S LABORATORIES LIMITED: DEALS, JANUARY 2022–SEPTEMBER 2025
483
TABLE 686
DIVI'S LABORATORIES LIMITED: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
484
TABLE 687
ASYMCHEM INC.: COMPANY OVERVIEW
485
TABLE 688
ASYMCHEM INC.: PRODUCTS OFFERED
486
TABLE 689
ASYMCHEM INC.: DEALS, JANUARY 2022–SEPTEMBER 2025
487
TABLE 690
ASYMCHEM INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
487
TABLE 691
CIPLA: COMPANY OVERVIEW
489
TABLE 692
CIPLA: PRODUCTS OFFERED
490
TABLE 693
CIPLA: DEALS, JANUARY 2022–SEPTEMBER 2025
492
TABLE 694
EVONIK: COMPANY OVERVIEW
494
TABLE 695
EVONIK: PRODUCTS OFFERED
495
TABLE 696
EVONIK: DEALS, JANUARY 2022–SEPTEMBER 2025
496
TABLE 697
EVONIK: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
497
TABLE 698
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
499
TABLE 699
TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
500
TABLE 700
TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025
509
TABLE 701
SANDOZ GROUP AG: COMPANY OVERVIEW
510
TABLE 702
SANDOZ GROUP AG: PRODUCTS OFFERED
511
TABLE 703
SANDOZ GROUP AG: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
513
TABLE 704
SK INC.: COMPANY OVERVIEW
514
TABLE 705
SK INC.: PRODUCTS OFFERED
515
TABLE 706
SK INC.: DEALS, JANUARY 2022–SEPTEMBER 2025
516
TABLE 707
SK INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
516
TABLE 708
MERCK KGAA: COMPANY OVERVIEW
518
TABLE 709
MERCK KGAA: PRODUCTS OFFERED
519
TABLE 710
MERCK KGAA: DEALS, JANUARY 2022–SEPTEMBER 2025
520
TABLE 711
MERCK KGAA: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
521
TABLE 712
DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW
522
TABLE 713
DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED
523
TABLE 714
DR. REDDY’S LABORATORIES LTD.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
525
TABLE 715
DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025
525
TABLE 716
SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
526
TABLE 717
SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
527
TABLE 718
SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025
529
TABLE 719
AUROBINDO PHARMA LIMITED: COMPANY OVERVIEW
530
TABLE 720
AUROBINDO PHARMA: PRODUCTS OFFERED
531
TABLE 721
AUROBINDO PHARMA: DEALS, JANUARY 2022–SEPTEMBER 2025
532
TABLE 722
HIKMA PHARMACEUTICALS PLC: COMPANY OVERVIEW
533
TABLE 723
HIKMA PHARMACEUTICALS PLC: PRODUCTS OFFERED
534
TABLE 724
HIKMA PHARMACEUTICALS PLC: DEALS, JANUARY 2022–SEPTEMBER 2025
535
TABLE 725
HIKMA PHARMACEUTICALS PLC: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
535
TABLE 726
BASF: COMPANY OVERVIEW
536
TABLE 727
BASF: PRODUCTS OFFERED
537
TABLE 728
ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
539
TABLE 729
ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
540
TABLE 730
ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025
541
TABLE 731
SIEGFRIED HOLDING AG: COMPANY OVERVIEW
542
TABLE 732
SIEGFRIED HOLDING AG: PRODUCTS OFFERED
543
TABLE 733
SIEGFRIED HOLDING AG: DEALS, JANUARY 2022–SEPTEMBER 2025
544
TABLE 734
SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
545
TABLE 735
EUROAPI: COMPANY OVERVIEW
546
TABLE 736
EUROAPI: PRODUCTS OFFERED
547
TABLE 737
EUROAPI: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
547
TABLE 738
BACHEM: COMPANY OVERVIEW
548
TABLE 739
BAYCHEM: PRODUCTS OFFERED
549
TABLE 740
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
551
TABLE 741
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
551
TABLE 742
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
553
TABLE 743
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
553
TABLE 744
POLYPEPTIDE GROUP: COMPANY OVERVIEW
555
TABLE 745
GRANULES INDIA: COMPANY OVERVIEW
556
TABLE 746
CORDEN PHARMA: COMPANY OVERVIEW
557
TABLE 747
RECIPHARMA: COMPANY OVERVIEW
558
TABLE 748
ABURAIHAN PHARMACEUTICAL COMPANY: COMPANY OVERVIEW
559
TABLE 749
CURIA GLOBAL, INC.: COMPANY OVERVIEW
560
TABLE 750
CAMBREX CORPORATION: COMPANY OVERVIEW
561
TABLE 751
API PHARMA TECH: COMPANY OVERVIEW
562
TABLE 752
SREEPATHI PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
563
TABLE 753
SHILPA MEDICARE LIMITED: COMPANY OVERVIEW
564
TABLE 754
NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
565
TABLE 755
HOVIONE: COMPANY OVERVIEW
566
TABLE 756
CHEMCON GMBH: COMPANY OVERVIEW
567
TABLE 757
PHARCO PHARMACEUTICALS: COMPANY OVERVIEW
567
TABLE 758
SAMBI PHARMA PVT. LTD.: COMPANY OVERVIEW
568
LIST OF FIGURES
FIGURE 1
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & REGIONAL SCOPE
51
FIGURE 2
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: YEARS CONSIDERED
52
FIGURE 3
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH DESIGN
54
FIGURE 4
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY DATA FROM SECONDARY SOURCES
56
FIGURE 5
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
57
FIGURE 6
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
58
FIGURE 7
COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024
59
FIGURE 8
REVENUE SHARE ANALYSIS OF PFIZER, INC., 2024
59
FIGURE 9
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE VALIDATION FROM PRIMARY SOURCES
61
FIGURE 10
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TOP-DOWN APPROACH
62
FIGURE 11
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CAGR PROJECTIONS
63
FIGURE 12
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DATA TRIANGULATION
65
FIGURE 13
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2025 VS. 2030 (USD BILLION)
70
FIGURE 14
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2025 VS. 2030 (USD BILLION)
70
FIGURE 15
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2025 VS. 2030 (USD BILLION)
71
FIGURE 16
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2025 VS. 2030 (USD BILLION)
71
FIGURE 17
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD BILLION)
72
FIGURE 18
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
73
FIGURE 19
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2025–2030
74
FIGURE 20
INCREASING DRUG R&D PIPELINE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
76
FIGURE 21
INNOVATIVE APIS AND US TO LEAD NORTH AMERICAN MARKET IN 2025
77
FIGURE 22
SYNTHETIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
77
FIGURE 23
MONOCLONAL ANTIBODIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
78
FIGURE 24
CHINA TO LEAD MARKET DURING FORECAST PERIOD
78
FIGURE 25
EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
79
FIGURE 26
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
82
FIGURE 27
GLOBAL PHARMACEUTICAL R&D SPENDING, 2023–2030, (USD BILLION)
86
FIGURE 28
NEW REVENUE POCKETS FOR PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
93
FIGURE 29
INDICATIVE PRICING ANALYSIS OF API, BY TYPE, 2024
95
FIGURE 30
INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2024
96
FIGURE 31
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: SUPPLY CHAIN ANALYSIS
99
FIGURE 32
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: VALUE CHAIN ANALYSIS
101
FIGURE 33
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ECOSYSTEM ANALYSIS
102
FIGURE 34
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS
111
FIGURE 35
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
113
FIGURE 36
KEY BUYING CRITERIA FOR END USERS
114
FIGURE 37
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
119
FIGURE 38
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT AND FUNDING SCENARIO, 2025 (USD MILLION)
127
FIGURE 39
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AI USE CASES
132
FIGURE 40
NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
289
FIGURE 41
ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
349
FIGURE 42
REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2022–2024 (USD MILLION)
451
FIGURE 43
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
453
FIGURE 44
EV/EBITDA OF KEY VENDORS
455
FIGURE 45
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BRAND/PRODUCT COMPARISON
457
FIGURE 46
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
459
FIGURE 47
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY FOOTPRINT
460
FIGURE 48
ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
467
FIGURE 49
PFIZER INC.: COMPANY SNAPSHOT (2024)
477
FIGURE 50
DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2024)
481
FIGURE 51
ASYMCHEM INC.: COMPANY SNAPSHOT (2024)
486
FIGURE 52
CIPLA: COMPANY SNAPSHOT (2024)
490
FIGURE 53
EVONIK: COMPANY SNAPSHOT (2024)
495
FIGURE 54
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
500
FIGURE 55
SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)
511
FIGURE 56
SK INC.: COMPANY SNAPSHOT (2024)
515
FIGURE 57
MERCK KGAA: COMPANY SNAPSHOT (2024)
519
FIGURE 58
DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2024)
523
FIGURE 59
SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
527
FIGURE 60
AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2024)
531
FIGURE 61
HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024)
534
FIGURE 62
BASF: COMPANY SNAPSHOT (2024)
537
FIGURE 63
ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)
540
FIGURE 64
SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024)
543
FIGURE 65
EUROAPI: COMPANY SNAPSHOT (2024)
546
FIGURE 66
BAYCHEM: COMPANY SNAPSHOT (2024)
549
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global active pharmaceutical ingredients market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the active pharmaceutical ingredients market. The secondary sources used for this study include Active Pharmaceutical Ingredients Committee (APIC), Chemical Pharmaceutical Generic Association (CPA), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), International Pharmaceutical Congress Advisory Association (IPCAA), European Generic and Biosimilar Medicines Association (EGBMA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), International Trade Centre (ITC), Press Releases, Company Websites, and Magazines & Proprietary Databases. Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Following an initial assessment of the global active pharmaceutical ingredients market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both bottom-up and top-down approaches were used to estimate and validate the total size of the active pharmaceutical ingredients market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- A list of the major global players operating in the active pharmaceutical ingredients market was generated.
- The revenues generated from their active pharmaceutical ingredients product have been determined through annual reports and secondary sources (including paid databases)
- The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
- All assumptions, approaches, and individual shares/revenue estimates were validated through interviews with experts.
Global Active Pharmaceutical Ingredients Market Size: Bottom-up and Top-down Approach
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Active Pharmaceutical Ingredients (API), also known as bulk pharmaceuticals or drug substances, are the primary biologically active components in medications that produce the intended therapeutic effect. These substances are responsible for the pharmacological activity of the drug product.
Stakeholders
- Manufacturers of APIs
- Distributors and Suppliers of APIs
- Potential Investors in the APIs Market
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Manufacturing Organizations
- Life Science Research Centers
- Healthcare Payers
- Academic and Government Research Institutes
- Venture Capitalists and Investors
- Government Organizations
- Private Research Firms
- Contract Research Organizations (CROs)
Report Objectives
- To define, describe, and forecast the active pharmaceutical ingredients market based on type, synthesis, type of drug, potency, therapeutic applications, end user, and region
- To provide detailed information on the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the active pharmaceutical ingredients market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions—North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global active pharmaceutical ingredients market and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product approvals and launches, expansions, agreements, and collaborations in the active pharmaceutical ingredients market
- To benchmark players within the active pharmaceutical ingredients market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategyn
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Active Pharmaceutical Ingredients (API) Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationGrowth opportunities and latent adjacency in Active Pharmaceutical Ingredients (API) Market
Hemanta
Jun, 2020
please help me to get API Drug Customers.